about
Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence"Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients.[Mastocytosis: revisited with new cytogenetic data].mRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switchmiRNA expression in anaplastic thyroid carcinomas.MiRNA expression may account for chronic but not for acute regulation of mRNA expression in human thyroid tumor models.Parathyroid carcinoma: a review with three illustrative cases.Revisiting the transcriptional analysis of primary tumours and associated nodal metastases with enhanced biological and statistical controls: application to thyroid cancer.New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.Management of salivary gland tumors.Follow-up strategies in head and neck cancer other than upper aerodigestive tract squamous cell carcinoma.Role of Epac and protein kinase A in thyrotropin-induced gene expression in primary thyrocytes.Quality-of-Life Priorities in Patients with Thyroid Cancer: A Multinational European Organisation for Research and Treatment of Cancer Phase I Study.microRNA expression in autonomous thyroid adenomas: Correlation with mRNA regulation.Intratumor heterogeneity and clonal evolution in an aggressive papillary thyroid cancer and matched metastases.Quality assurance in head and neck surgical oncology: EORTC 24954 trial on larynx preservation.Near infrared fluorescent imaging after intravenous injection of indocyanine green during neck dissection in patients with head and neck cancer: A feasibility study.Parathyroidectomy in primary hyperparathyroidism: retrospective study of 167 patients, experience in Jules Bordet Institute.Uvular and tonsillar pillar mucosal necrosis as a cause of severe sore throat after orotracheal intubation.Quality assurance in head and neck surgery: special considerations to catch upEORTC 24051: Unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinomaRecurrent invasive thymoma with pleural dissemination : disease management and treatment possibilities
P50
Q28391909-8F1C3672-2D78-495A-B7F6-BCFB75BCE86CQ30373904-AC6669DE-A32A-40BB-873F-1632A96767A5Q34237066-67B4D811-3D30-43BC-B9B6-C8A4893B9AA5Q34463393-40939956-3ED3-474B-9763-ED7818E1F699Q35230925-DE822E4B-EAE7-4DAD-A6C8-C1E212AD0247Q35399243-FE857035-E676-4CF4-8235-F94B9585D801Q35479870-B27EB78E-022E-4A4C-803A-09BCB362561FQ35603635-9F6B3957-77F9-4CC9-82A8-9D1E4FA84B24Q35815485-D4B0D97F-4EB1-44C4-98AA-4432C90F713DQ38055494-58E667B9-F884-4687-9D42-34E92C41DE6FQ38055702-0B5CD5C2-6E86-4BE0-A454-7F7626E7F185Q38328743-53F67260-B154-4AA1-852C-B20C209C7473Q40501848-EF850FC0-73A9-43ED-B85C-5958DAF59111Q41008605-7119EE4F-AC7D-422C-B7F2-29C9C486ADCAQ42776218-B2FF2B4B-F1FA-442F-A2A7-BA63FD68022DQ46484464-193CE555-0D2B-4BA4-8F61-814A602B760CQ47612118-27632A87-9C5E-45CA-84FE-93A363ED4569Q47836508-B1418C05-AD44-441E-9196-7E39E0DD59ABQ48240339-2B42927A-CFF5-4947-AF76-384D727A93B5Q58863174-0F70AAA4-D117-40A4-86C4-5A4A1355A80EQ61866232-CEA6B96B-89D1-4821-9FDF-5E539BCF008AQ85233981-E729F647-2A46-4180-90A9-74EC52E60972
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Guy Andry
@ast
Guy Andry
@en
Guy Andry
@es
Guy Andry
@nl
Guy Andry
@sl
type
label
Guy Andry
@ast
Guy Andry
@en
Guy Andry
@es
Guy Andry
@nl
Guy Andry
@sl
prefLabel
Guy Andry
@ast
Guy Andry
@en
Guy Andry
@es
Guy Andry
@nl
Guy Andry
@sl
P106
P21
P31
P496
0000-0001-7410-6519